-
About UsBeijing Northland Biotechnology Co., Ltd. is an innovative biopharmaceutical company specializing in the research, development, production, and sales of gene therapy drugs, recombinant protein drugs, and ophthalmic drugs. -
R&D and ProductsPrimarily dedicated to the research, development, and industrialization of novel bioengineered drugs in areas such as cardiovascular diseases, metabolic disorders, rare diseases, and ophthalmic diseases. -
Investor RelationsGuided by the principle of “Creating Value, Serving Health,” the company is committed to becoming an innovative biopharmaceutical enterprise, contributing to the advancement of China’s pharmaceutical industry and the well-being of humanity.
2023
March 1: The Phase IIb clinical trial NL005 has completed enrollment of all participants.
June 12: All 242 patients enrolled in the Phase III clinical trial NL003 for the ulcer indication have completed enrollment.
June 15: The main structure of the biopharmaceutical base has been topped out.
July 3: The first OTC product—0.1% (0.4 ml: 0.4 mg) sodium hyaluronate eye drops—has been approved.
August 6: Unblinding of Phase IIb clinical trial data for the company’s NL005 project.
August 10: “Diquafosol Sodium Eye Drops” received the “Drug Registration Certificate.”
September 26: The company passed the pharmaceutical GMP compliance inspection.
November 6: Sodium Diclofenac Eye Drops Successfully Won the Bid in the Ninth Round of National Centralized Drug Procurement.
November 21: The company was approved to establish a postdoctoral innovation and practice base.
December 5: All 302 patients enrolled in the NL003 Phase III clinical trial for the indication of resting pain have completed enrollment.
December 9: The production of the registered batch samples for NL003 has been successfully completed.
Share to:
Friendly Links: Baidu | NORTHLAND
Contact Information
Address: Room A406, Zhongguancun Biomedical Park, No. 5 Kaituo Road, Shangdi, Haidian District, Beijing
Follow Us
Northland is an innovative biopharmaceutical company specializing in the R&D, manufacturing and sales of gene therapy drugs, recombinant protein drugs and ophthalmic medications.
Web site
NL-BIO
NL003
NL005